IN CASE YOU MISSED IT: This week, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around reforming the patent system to balance competition and innovation so that American patients have access to affordable drugs, especially as both the private and public sectors work to quickly discover a treatment for COVID-19.  […]

Continue Reading

IN CASE YOU MISSED IT: Recently, HealthAffairs highlighted a study by researchers at Brigham and Women’s Hospital and Harvard Medical School that showed the real effects of name-brand drug manufacturers maintaining their market exclusivity by preventing of generic competition from entering the marketplace.  Among 61 name-brand drugs at risk of losing their market exclusivity from 2010-2016, 45 […]

Continue Reading

IN CASE YOU MISSED IT: This week, Townhall published an op-ed by Wayne Brough, President of the Innovation Defense Foundation, on the challenging task policymakers have in thwarting threats that could hinder the nation’s economic recovery from COVID-19.  As we work as a nation to financially rebuild, lawmakers must also consider the constrains that bad patent laws can have […]

Continue Reading

IN CASE YOU MISSED IT: Recently, The Hill published a timely op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse.  Lane penned this piece amidst the COVID-19 pandemic to highlight the need to make sure our drug laws are working to encourage innovation and public-private partnerships for the development of needed drugs while preventing […]

Continue Reading

By Matthew Lane, Executive Director of the Coalition Against Patent Abuse (CAPA) On March 9, 2020, the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) held a public workshop to discuss their collaborative efforts to support appropriate adoption of biosimilars, discourage false or misleading statements about biosimilars, and deter anticompetitive behaviors in the […]

Continue Reading

WASHINGTON, DC: On the 10th anniversary of the Biologics Price Competition and Innovation Act (BPCIA) that created biosimilars, The ERISA Industry Committee (ERIC) released a study on the potential savings employers and employees could have with increased biosimilars in the marketplace.  Inside Health Politicscovered the study which found that biologics – the most expensive class of […]

Continue Reading

IN CASE YOU MISSED IT: Yesterday, Slate published a must-read op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this thought-provoking and timely piece, Lane highlights the importance of ensuring transparency around the taxpayer costs for COVID-19 drug research so American patients are guaranteed a fair price when a coronavirus drug comes to […]

Continue Reading

IN CASE YOU MISSED IT: As first reported by Axios, a new must-read study from the JAMA Network found that between 2007 and 2018, the net price of brand-name prescription drugs rose by 60 percent. These findings underscore the financial challenges faced by American patients trying to afford the often life-saving prescription drugs they need. A significant driver of […]

Continue Reading

IN CASE YOU MISSED IT: While American patients struggle to pay for their prescription drugs, Big Pharma is spending unprecedented amounts on efforts to prevent more affordable medications and treatments. Recent reporting from STAT News and Politico Pro found that in 2019, the trade group PhRMA spent over $28.9 million to lobby Congress. This influx of […]

Continue Reading

IN CASE YOU MISSED IT: On Friday, Roll Call published the below op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse. In this thought-provoking piece, Lane praises the bipartisan efforts of last year, notably those of Senators Richard Blumenthal (D-CT) and John Cornyn (R-TX), to rein in Big Pharma and lower prescription drug prices. […]

Continue Reading